Immunomaintenance therapy is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) and Fujian Cancer Hospital (1). Registered phase: Phase 3. Conditions studied include Locally Advanced Cervical Carcinoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07400536 | A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (ClinicalTrials.gov ↗) Locally Advanced Cervical Carcinoma |
Phase 3 | Recruiting |
| NCT07613567 | A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer (ClinicalTrials.gov ↗) Locally Advanced Cervical Carcinoma |
Phase 3 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Locally Advanced Cervical Carcinoma | 2 |
| Lead sponsor | Trials |
|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Fujian Cancer Hospital | 1 |
| Register | Immunomaintenance therapy trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Immunomaintenance therapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Immunomaintenance therapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.